LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 70

Search options

  1. Article ; Online: Pharmacological approaches to target type 2 cytokines in asthma.

    Guilleminault, Laurent / Conde, Eva / Reber, Laurent L

    Pharmacology & therapeutics

    2022  Volume 237, Page(s) 108167

    Abstract: Asthma is the most common chronic lung disease, affecting more than 250 million people worldwide. The heterogeneity of asthma phenotypes represents a challenge for adequate assessment and treatment of the disease. However, approximately 50% of asthma ... ...

    Abstract Asthma is the most common chronic lung disease, affecting more than 250 million people worldwide. The heterogeneity of asthma phenotypes represents a challenge for adequate assessment and treatment of the disease. However, approximately 50% of asthma patients present with chronic type 2 inflammation initiated by alarmins, such as IL-33 and thymic stromal lymphopoietin (TSLP), and driven by the T
    MeSH term(s) Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Asthma ; Cytokines/metabolism ; Humans
    Chemical Substances Antibodies, Monoclonal ; Cytokines
    Language English
    Publishing date 2022-03-10
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 194735-7
    ISSN 1879-016X ; 0163-7258
    ISSN (online) 1879-016X
    ISSN 0163-7258
    DOI 10.1016/j.pharmthera.2022.108167
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Un vaccin ciblant les cytokines IL-4 et IL-13 protège contre l’asthme allergique chez la souris.

    Conde, Eva / Serra, Vincent / Bruhns, Pierre / Reber, Laurent L

    Medecine sciences : M/S

    2022  Volume 38, Issue 1, Page(s) 25–27

    Title translation A vaccine targeting the cytokines IL-4 and IL-13 protects against allergic asthma in mice.
    MeSH term(s) Animals ; Asthma/prevention & control ; Cytokines ; Disease Models, Animal ; Humans ; Interleukin-13 ; Interleukin-4 ; Mice ; Mice, Inbred BALB C ; Th2 Cells ; Vaccines
    Chemical Substances Cytokines ; Interleukin-13 ; Vaccines ; Interleukin-4 (207137-56-2)
    Language French
    Publishing date 2022-01-21
    Publishing country France
    Document type News
    ZDB-ID 632733-3
    ISSN 1958-5381 ; 0767-0974
    ISSN (online) 1958-5381
    ISSN 0767-0974
    DOI 10.1051/medsci/2021232
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Increased fermentable carbohydrate intake alters colonic mucus barrier function through glycation processes and increased mast cell counts.

    Kamphuis, J B J / Reber, Laurent / Eutamène, H / Theodorou, V

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

    2022  Volume 36, Issue 5, Page(s) e22297

    Abstract: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder for which dietary interventions can be a useful treatment. In recent years, the low-FODMAP approach is gaining traction in this regard. The fermentation of these non-absorbed ... ...

    Abstract Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder for which dietary interventions can be a useful treatment. In recent years, the low-FODMAP approach is gaining traction in this regard. The fermentation of these non-absorbed carbohydrates by the gut microbiota can generate toxic glycating metabolites, such as methylglyoxal. These metabolites can have harmful effects by their role in the generation of advanced glycation end products (AGEs), which activates Receptor for AGEs (AGER). Mast cells can be stimulated by AGEs and play a role in IBS. We have treated mice with lactose or fructo-oligosaccharides (FOS), with or without co-administration of pyridoxamine and investigated the colonic mucus barrier. We have found that an increased intake of lactose and fructo-oligosaccharides induces a dysregulation of the colonic mucus barrier, increasing mucus discharge in empty colon, while increasing variability and decreasing average thickness mucus layer covering the fecal pellet. Changes were correlated with increased mast cell counts, pointing to a role for the crosstalk between these and goblet cells. Additionally, AGE levels in colonic epithelium were increased by treatment with the selected fermentable carbohydrates. Observed effects were prevented by co-treatment with anti-glycation agent pyridoxamine, implicating glycation processes in the negative impact of fermentable carbohydrate ingestion. This study shows that excessive intake of fermentable carbohydrates can cause colonic mucus barrier dysregulation in mice, by a process that involves glycating agents and increased mucosal mast cell counts.
    MeSH term(s) Animals ; Cell Count ; Irritable Bowel Syndrome ; Lactose/pharmacology ; Mice ; Mucus/metabolism ; Oligosaccharides/metabolism ; Pyridoxamine
    Chemical Substances Oligosaccharides ; Pyridoxamine (6466NM3W93) ; Lactose (J2B2A4N98G)
    Language English
    Publishing date 2022-04-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639186-2
    ISSN 1530-6860 ; 0892-6638
    ISSN (online) 1530-6860
    ISSN 0892-6638
    DOI 10.1096/fj.202100494RRR
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Parasitic Infections and Biological Therapies Targeting Type 2 Inflammation: A VigiBase Study.

    Lifar, Philippine / Montastruc, François / Reber, Laurent L / Magnaval, Jean-François / Guilleminault, Laurent

    American journal of respiratory and critical care medicine

    2023  Volume 207, Issue 9, Page(s) 1253–1255

    MeSH term(s) Humans ; Asthma ; Parasitic Diseases ; Biological Therapy ; Inflammation
    Language English
    Publishing date 2023-03-08
    Publishing country United States
    Document type Letter
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202210-1898LE
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The economic burden of asthma prior to death: a nationwide descriptive study.

    Guilleminault, Laurent / Mounié, Michael / Sommet, Agnès / Camus, Claire / Didier, Alain / Reber, Laurent Lionel / Conte, Cécile / Costa, Nadège

    Frontiers in public health

    2024  Volume 12, Page(s) 1191788

    Abstract: Background: In addition to the clinical burden, asthma is responsible for a high economic burden. However, little is known about the economic burden of asthma prior to death.: Objective: We performed an economic analysis to describe the costs during ... ...

    Abstract Background: In addition to the clinical burden, asthma is responsible for a high economic burden. However, little is known about the economic burden of asthma prior to death.
    Objective: We performed an economic analysis to describe the costs during 12 and 24 months prior to asthma death between 2013 and 2017 in France.
    Methods: An observational cohort study was established using the French national health insurance database. Direct medical and non-medical costs, as well as costs related to absence from the workplace, were included in the analysis.
    Results: In total, 3,829 patients were included in the final analysis. Over 24 and 12 months prior to death, total medical costs per patient were €27,542 [26,545-28,641] and €16,815 [16,164-17,545], respectively. Total medical costs clearly increased over 24 months prior to death. Over 12 months prior to death, costs increased significantly according to age categories, with mean total costs of €8,592, €15,038, and €17,845, respectively, for the categories <18 years old, 18-75 years old, and 75+ years old (
    Conclusion: To conclude, the economic burden of asthma death is high and increases with time, age, and SABA dispensation.
    MeSH term(s) Humans ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged ; Financial Stress ; Asthma ; Databases, Factual ; France/epidemiology ; Hospitals
    Language English
    Publishing date 2024-02-19
    Publishing country Switzerland
    Document type Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2711781-9
    ISSN 2296-2565 ; 2296-2565
    ISSN (online) 2296-2565
    ISSN 2296-2565
    DOI 10.3389/fpubh.2024.1191788
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.

    Guilleminault, Laurent / Michelet, Marine / Reber, Laurent Lionel

    Clinical reviews in allergy & immunology

    2021  Volume 62, Issue 1, Page(s) 216–231

    Abstract: Immunoglobulin E (IgE)-mediated food allergy is a real public health problem worldwide. The prevalence of food allergy is particularly high in children. Patients with food allergy experience high morbidity with a change in quality of life due to the risk ...

    Abstract Immunoglobulin E (IgE)-mediated food allergy is a real public health problem worldwide. The prevalence of food allergy is particularly high in children. Patients with food allergy experience high morbidity with a change in quality of life due to the risk of severe anaphylaxis. Current treatment options are poor. Allergen avoidance is widely recommended but exposes patients to accidental ingestion. Oral immunotherapy is also used in patients with food allergies to the most common allergens. Oral immunotherapy consists of a daily administration of small, gradually increasing amounts of allergens to induce desensitisation. This procedure aims at inducing immune tolerance to the ingested food allergens. However, some patients experience adverse reactions and discontinue oral immunotherapy.Given that IgE plays a crucial role in food allergy and anti-IgE are effective in allergic asthma, the use of anti-IgE therapeutic monoclonal antibodies (mAbs) such as omalizumab has been assessed in food allergy patients. The use of omalizumab as a monotherapy in food allergy has not been extensively studied but looks promising. There is more published evidence regarding the effect of omalizumab and oral immunotherapy in food allergy. Given the promising results of oral immunotherapy regarding sustained tolerance in clinical trials and the potential capacity of omalizumab to reduce symptoms in case of accidental exposure, a strategy combining oral immunotherapy with omalizumab pre-treatment has been suggested as a safer option in patients with severe food allergy compared to isolated therapy. Omalizumab seems useful in ensuring safer administration of oral immunotherapy with the oral immunotherapy maintenance dose being reached more rapidly. Quality-of-life improvement is greater with oral immunotherapy + omalizumab compared to oral immunotherapy alone. Moreover, sustained unresponsiveness is achieved more frequently with omalizumab. Considering that precision medicine and personalised therapy are major goals for allergic diseases, predictive biomarkers are crucial in order to identify food allergy patients more likely to benefit from anti-IgE therapies.
    MeSH term(s) Allergens ; Antibodies, Anti-Idiotypic ; Child ; Desensitization, Immunologic/methods ; Food Hypersensitivity ; Humans ; Immunotherapy/methods ; Omalizumab/therapeutic use ; Quality of Life
    Chemical Substances Allergens ; Antibodies, Anti-Idiotypic ; anti-IgE antibodies ; Omalizumab (2P471X1Z11)
    Language English
    Publishing date 2021-09-22
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1239045-8
    ISSN 1559-0267 ; 1080-0549
    ISSN (online) 1559-0267
    ISSN 1080-0549
    DOI 10.1007/s12016-021-08902-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: [PMN

    Gillis, Caitlin M / Reber, Laurent L

    Medecine sciences : M/S

    2018  Volume 34, Issue 4, Page(s) 339–343

    Abstract: Neutrophils play a key role in host defense against pathogens. They can contribute to pathological inflammation, and are thought to exacerbate tissue injury upon exposure to bacterial products, such as endotoxin (LPS). Recent findings suggest that ... ...

    Title translation Un nouveau modèle de souris pour comprendre le rôle des neutrophiles.
    Abstract Neutrophils play a key role in host defense against pathogens. They can contribute to pathological inflammation, and are thought to exacerbate tissue injury upon exposure to bacterial products, such as endotoxin (LPS). Recent findings suggest that neutrophils can also participate in adaptive immune responses and contribute to inflammation resolution. Many discoveries regarding the in vivo role of neutrophils were made possible by the use of genetically modified neutrophil-deficient mice, or by the use of neutrophil-depleting antibodies. Here we describe a new mouse model, PMN
    MeSH term(s) Animals ; Diphtheria Toxin ; Disease Models, Animal ; Drug Resistance/genetics ; Heparin-binding EGF-like Growth Factor/genetics ; Heparin-binding EGF-like Growth Factor/metabolism ; Humans ; Inflammation/genetics ; Inflammation/immunology ; Mice ; Mice, Transgenic ; Neutropenia/chemically induced ; Neutropenia/genetics ; Neutropenia/pathology ; Neutrophils/metabolism ; Neutrophils/physiology ; Shock, Septic/genetics ; Shock, Septic/immunology
    Chemical Substances Diphtheria Toxin ; Heparin-binding EGF-like Growth Factor
    Language French
    Publishing date 2018-04-16
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 632733-3
    ISSN 1958-5381 ; 0767-0974
    ISSN (online) 1958-5381
    ISSN 0767-0974
    DOI 10.1051/medsci/20183404015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Editorial: Role of Neutrophils in Inflammatory Diseases.

    Marichal, Thomas / Boyman, Onur / Reber, Laurent L

    Frontiers in immunology

    2020  Volume 11, Page(s) 627939

    MeSH term(s) Humans ; Immunity, Innate ; Inflammation/immunology ; Inflammation/pathology ; Neutrophils/immunology ; Neutrophils/pathology
    Language English
    Publishing date 2020-12-08
    Publishing country Switzerland
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2020.627939
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Mouse Models and Tools for the

    Stackowicz, Julien / Jönsson, Friederike / Reber, Laurent L

    Frontiers in immunology

    2020  Volume 10, Page(s) 3130

    Abstract: Neutrophils are the most abundant leukocytes in human blood and critical actors of the immune system. Many neutrophil functions and facets of their ... ...

    Abstract Neutrophils are the most abundant leukocytes in human blood and critical actors of the immune system. Many neutrophil functions and facets of their activity
    MeSH term(s) Animals ; Humans ; Mice ; Models, Animal ; Neutrophils/immunology
    Language English
    Publishing date 2020-01-21
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2019.03130
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: IgE in the pathophysiology and therapy of food allergy.

    Michelet, Marine / Balbino, Bianca / Guilleminault, Laurent / Reber, Laurent L

    European journal of immunology

    2021  Volume 51, Issue 3, Page(s) 531–543

    Abstract: Food allergy is becoming a major public health issue, with no regulatory approved therapy to date. Food allergy symptoms range from skin rash and gastrointestinal symptoms to anaphylaxis, a potentially fatal systemic allergic shock reaction. IgE ... ...

    Abstract Food allergy is becoming a major public health issue, with no regulatory approved therapy to date. Food allergy symptoms range from skin rash and gastrointestinal symptoms to anaphylaxis, a potentially fatal systemic allergic shock reaction. IgE antibodies are thought to contribute importantly to key features of food allergy and anaphylaxis, and measurement of allergen-specific IgE is fundamental in diagnosing food allergy. This review will discuss recent advances in the regulation of IgE production and IgE repertoires in food allergy. We will describe the current understanding of the role of IgE and its high-affinity receptor FcεRI in food allergy and anaphylaxis, by reviewing insights gained from analyses of mouse models. Finally, we will review data derived from clinical studies of the effect of anti-IgE therapeutic monoclonal antibodies (mAbs) in food allergy, and recent insight on the efficiency and mechanisms through which these mAbs block IgE effector functions.
    MeSH term(s) Anaphylaxis/immunology ; Animals ; Antibodies, Monoclonal/immunology ; Food Hypersensitivity/immunology ; Humans ; Immunoglobulin E/immunology ; Receptors, IgE/immunology
    Chemical Substances Antibodies, Monoclonal ; Receptors, IgE ; Immunoglobulin E (37341-29-0)
    Language English
    Publishing date 2021-02-17
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 120108-6
    ISSN 1521-4141 ; 0014-2980
    ISSN (online) 1521-4141
    ISSN 0014-2980
    DOI 10.1002/eji.202048833
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top